Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis
Keywords:atopic dermatitis, economic burden, humanistic burden, pediatric, health-related quality of life
Data concerning the economic and humanistic burden in patients with paediatric atopic dermatitis (AD) and their families are scarce. This retrospective study investigated these burdens in paediatric patients with AD using maintenance treatment with topical corticosteroids and/or conventional systemic immunosuppressants. Patient-reported outcomes regarding quality of life, AD severity, and parental work-related impairment were completed at inclusion. Data on healthcare resource utilization and medication prescription were collected retrospectively over the previous 12 months. Patients were categorized into mild, moderate or severe AD, based on Eczema Area and Severity Index score and medication use. Costs per patient per year per AD severity category were calculated. A total of 101 patients (median age 11.0 years (interquartile range 7.5–14.0), 47.5% men) were included, of whom 38 had mild AD, 37 moderate AD, and 26 severe AD. Mean ± standard deviation (SD) total costs patient per year for mild, moderate and severe AD were €1,812 ± €1,280, €2,680 ± €3,127, and €5,861 ± €3,993, respectively. Highest total direct and indirect costs were found in patients with severe AD, mainly due to higher healthcare and medication costs. Highest humanistic burden was found in patients with moderate AD. For example, the median (interquartile range) Patient-Oriented Eczema Measure score was significantly higher in these patients compared with mild and severe AD (19.0 (15.0–24.0) vs 12.0 (8.8–15.0) and 17.0 (9.5–22.0), respectively). AD in paediatric patients incurs considerable direct and indirect costs, especially in patients with severe AD. The high humanistic burden in patients with moderate AD underlines the need for effective and safe new treatment options for children with AD.
Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733-743.
https://doi.org/10.1016/S0140-6736(06)69283-0 DOI: https://doi.org/10.1016/S0140-6736(06)69283-0
Bylund S, Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol 2020; 100: adv00160.
https://doi.org/10.2340/00015555-3510 DOI: https://doi.org/10.2340/00015555-3510
Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis 2014; 25: 107-114.
https://doi.org/10.1097/DER.0000000000000034 DOI: https://doi.org/10.1097/DER.0000000000000034
Filanovsky MG, Pootongkam S, Tamburro JE, Smith MC, Ganocy SJ, Nedorost ST. The financial and emotional impact of atopic dermatitis on children and their families. J Pediatr 2016; 169: 284-290.e5.
https://doi.org/10.1016/j.jpeds.2015.10.077 DOI: https://doi.org/10.1016/j.jpeds.2015.10.077
Hebert AA, Stingl G, Ho LK, Lynde C, Cappelleri JC, Tallman AM, et al. Patient impact and economic burden of mild-to-moderate atopic dermatitis. Curr Med Res Opin 2018; 34: 2177-2185.
https://doi.org/10.1080/03007995.2018.1498329 DOI: https://doi.org/10.1080/03007995.2018.1498329
Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB, Jr., Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005; 22: 192-199.
https://doi.org/10.1111/j.1525-1470.2005.22303.x DOI: https://doi.org/10.1111/j.1525-1470.2005.22303.x
Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic dermatitis in america study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol 2019; 139: 583-590.
https://doi.org/10.1016/j.jid.2018.08.028 DOI: https://doi.org/10.1016/j.jid.2018.08.028
Olsson M, Bajpai R, Wee LWY, Yew YW, Koh MJA, Thng S, et al. The cost of childhood atopic dermatitis in a multi-ethnic Asian population: a cost-of-illness study. Br J Dermatol 2020; 182: 1245-1252.
https://doi.org/10.1111/bjd.18442 DOI: https://doi.org/10.1111/bjd.18442
Ariens LFM, van Nimwegen KJM, Shams M, de Bruin DT, van der Schaft J, van Os-Medendorp H, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol 2019; 99: 762-768.
https://doi.org/10.2340/00015555-3212 DOI: https://doi.org/10.2340/00015555-3212
Ricci G, Bendandi B, Pagliara L, Patrizi A, Masi M. Atopic dermatitis in Italian children: evaluation of its economic impact. J Pediatr Health Care 2006; 20: 311-315.
https://doi.org/10.1016/j.pedhc.2006.04.009 DOI: https://doi.org/10.1016/j.pedhc.2006.04.009
Weil C, Sugerman PB, Chodick G, Liang H, Wang H, Calimlim BM, et al. Epidemiology and economic burden of atopic dermatitis: real-world retrospective data from a large nationwide Israeli Healthcare Provider Database. Adv Ther 2022; 39: 2502-2514.
https://doi.org/10.1007/s12325-022-02120-6 DOI: https://doi.org/10.1007/s12325-022-02120-6
Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002; 147: 716-724.
https://doi.org/10.1046/j.1365-2133.2002.04964.x DOI: https://doi.org/10.1046/j.1365-2133.2002.04964.x
Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol 2008; 25: 1-6.
https://doi.org/10.1111/j.1525-1470.2007.00572.x DOI: https://doi.org/10.1111/j.1525-1470.2007.00572.x
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 44-56.
https://doi.org/10.1001/jamadermatol.2019.3336 DOI: https://doi.org/10.1001/jamadermatol.2019.3336
Paller AS, Siegfried EC, Thaci D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020; 83: 1282-1293.
https://doi.org/10.1016/j.jaad.2020.06.054 DOI: https://doi.org/10.1016/j.jaad.2020.06.054
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169-2181.
https://doi.org/10.1016/S0140-6736(21)00589-4 DOI: https://doi.org/10.1016/S0140-6736(21)00589-4
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
https://doi.org/10.1034/j.1600-0625.2001.100102.x DOI: https://doi.org/10.1034/j.1600-0625.2001.100102.x
Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017; 177: 1316-1321.
https://doi.org/10.1111/bjd.15641 DOI: https://doi.org/10.1111/bjd.15641
Guideline for conducting economic evaluations in health care (2015). National Health Care Institute, Diemen. Available from: www.zorginstituutnederland.nl.
Netherlands S. Consumer price index 2018. [accessed Jan 2021] Available from: http://statline.cbs.nl/StatWeb/publication/?VW=T&DM=SLNL&PA=83131ned.
Medicijnkosten.nl (2017). National Health Care Institute, Diemen. Available from: www.medicijnkosten.nl.
van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010; 69: i89-91.
https://doi.org/10.1136/ard.2009.117150 DOI: https://doi.org/10.1136/ard.2009.117150
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.
https://doi.org/10.1111/bjd.12590 DOI: https://doi.org/10.1111/bjd.12590
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-1519.
https://doi.org/10.1001/archderm.140.12.1513 DOI: https://doi.org/10.1001/archderm.140.12.1513
Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res 2010; 19: 875-886.
https://doi.org/10.1007/s11136-010-9648-y DOI: https://doi.org/10.1007/s11136-010-9648-y
Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-949.
https://doi.org/10.1111/j.1365-2133.1995.tb16953.x DOI: https://doi.org/10.1111/j.1365-2133.1995.tb16953.x
Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol 1998; 138: 107-113.
https://doi.org/10.1046/j.1365-2133.1998.02034.x DOI: https://doi.org/10.1046/j.1365-2133.1998.02034.x
Haverman L, Grootenhuis MA, Raat H, van Rossum MA, van Dulmen-den Broeder E, Hoppenbrouwers K, et al. Dutch-Flemish translation of nine pediatric item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS)®. Qual Life Res 2016; 25: 761-765.
https://doi.org/10.1007/s11136-015-0966-y DOI: https://doi.org/10.1007/s11136-015-0966-y
Terwee CB, Roorda LD, de Vet HC, Dekker J, Westhovens R, van Leeuwen J, et al. Dutch-Flemish translation of 17 item banks from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res 2014; 23: 1733-1741.
https://doi.org/10.1007/s11136-013-0611-6 DOI: https://doi.org/10.1007/s11136-013-0611-6
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-365.
https://doi.org/10.2165/00019053-199304050-00006 DOI: https://doi.org/10.2165/00019053-199304050-00006
Patient-Reported Outcomes Measurement Information System Anxiety, Dynamic Tools to Measure Health Outcomes From the Patient Perspective, 2015: 1-11.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Strat Soc 1995; 57: 289-300.
https://doi.org/10.1111/j.2517-6161.1995.tb02031.x DOI: https://doi.org/10.1111/j.2517-6161.1995.tb02031.x
IBM Corp. IBM SPSS Statistics for Windows, Version 26.0; IBM Corp.: Armonk, NY, USA, 2019. Available online:
Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8: 333-342.
https://doi.org/10.18553/jmcp.2002.8.5.333 DOI: https://doi.org/10.18553/jmcp.2002.8.5.333
Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76: 159-162.
https://doi.org/10.1136/adc.76.2.159 DOI: https://doi.org/10.1136/adc.76.2.159
Wollenberg A, Christen-Zach S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.
https://doi.org/10.1111/jdv.16892 DOI: https://doi.org/10.1111/jdv.16892
Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol 2018; 120: 10-22.e2.
https://doi.org/10.1016/j.anai.2017.10.039 DOI: https://doi.org/10.1016/j.anai.2017.10.039
Totri CR, Eichenfield LF, Logan K, Proudfoot L, Schmitt J, Lara-Corrales I, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol 2017; 76: 281-285.
https://doi.org/10.1016/j.jaad.2016.09.021 DOI: https://doi.org/10.1016/j.jaad.2016.09.021
Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226-232.
https://doi.org/10.1016/j.jaci.2006.02.031 DOI: https://doi.org/10.1016/j.jaci.2006.02.031
How to Cite
Copyright (c) 2023 Roselie Achten, Lisa van der Rijst, Marjanne Piena, Hedda Lamers, Fleur de Beer, Marjolein de Bruin-Weller, Marlies de Graaf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
All published articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.